Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
äŒæ¥ã³ãŒãOGN
äŒç€ŸåOrganon & Co
äžå Žæ¥May 14, 2021
æé«çµå¶è²¬ä»»è
ãCEOãMorrissey (Joseph T)
åŸæ¥å¡æ°10000
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«May 14
æ¬ç€Ÿæåšå°30 Hudson Street
éœåžJERSEY CITY
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·07302
é»è©±çªå·15514306000
ãŠã§ããµã€ãhttps://www.organon.com/
äŒæ¥ã³ãŒãOGN
äžå Žæ¥May 14, 2021
æé«çµå¶è²¬ä»»è
ãCEOãMorrissey (Joseph T)